Evolving Treatment and Best Practices in Early Relapsed Follicular Lymphoma: An Interview With Carla Casulo, MD

Accounting for about one third of non-Hodgkin lymphoma cases, follicular lymphoma is a heterogeneous cancer, making it difficult to treat. When a patient relapses or has refractory disease, it becomes an even more difficult challenge to treat. However, continued research has brought significant treatment advances. Carla Casulo, MD, Associate Professor at the University of Rochester Medical Center, has conducted extensive research on follicular lymphoma and treats many patients with this dis...
Continue reading

Cancer Risk Elevated for Nail Salon Workers: Interview With Aaron Lamplugh

When Aaron Lamplugh, PhD candidate at University of Colorado Boulder, and colleagues measured the levels of chemicals in six nail salons across Colorado, they discovered that nail salon technicians are exposed to many volatile organic compounds (VOCs) at levels that increase their risk of developing cancer. In this interview with i3 Health, Mr. Lamplugh shares insights regarding the implications that high levels of chemicals have on nail salon workers and suggests some ways to mitigate the effec...
Continue reading

Venetoclax for CLL/SLL With Matthew S. Davids, MD, MMSc

The FDA has recently expanded the label of venetoclax (Venclexta®, AbbVie Inc. and Genetech Inc.) to now include the treatment of adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), including those requiring initial therapy. Venetoclax is a targeted therapy that binds to the BCL-2 protein, which stimulates apoptosis—programmed cell death—in cancer cells. Matthew S. Davids, MD, MMSc, Assistant Professor at Harvard Medical School, and colleagues conducted earlier re...
Continue reading

Predicting and Managing Early Relapse in Follicular Lymphoma: An Interview With Carla Casulo, MD

Due to its heterogeneity, follicular lymphoma is a difficult cancer to treat. Often, patients experience relapse. Carla Casulo, MD, Associate Professor at the University of Rochester Medical Center, has done extensive research on follicular lymphoma and treats many patients with this disease. In an interview with i3 Health, Dr. Casulo shares insights on predicting and managing relapsed follicular lymphoma.What are some risk factors that could predict early relapse of follicular lymphoma?Dr....
Continue reading

Multiple Myeloma: bb2121 CAR T-Cell Therapy With James Kochenderfer, MD

Chimeric antigen receptor (CAR) T-cell therapy has shown great promise in hematologic malignancies, with treatments currently FDA approved for aggressive, refractory non-Hodgkin lymphoma and for relapsed/refractory acute lymphoblastic leukemia in patients up to the age of 25. Now, a phase 1 clinical trial of bb2121, a CAR T-cell therapy targeting B-cell maturation antigen (BCMA), has demonstrated antitumor activity in patients with heavily pretreated multiple myeloma. In this interview with i3 H...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.